OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies with new technologies to stimulate the body’s immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.
Our investigational platform, Intratumoral IL-12, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of Intratumoral IL-12 with plasmid encoded IL-12 (tavokinogene telseplasmid or “TAVO“) demonstrated a local immune response, and subsequently, systemic activity as either a monotherapy or combination treatment approach.
Currently, we are conducting pre-clinical and clinical studies targeting various cancers in collaboration with several prominent academic medical centers and companies. To date, study results have laid the groundwork for OncoSec’s expansion into new DNA-encoded therapeutic candidates and tumor indications. These results allow us to explore the broad applications of our proprietary technology and pursue potential combination therapies that address a great unmet medical need in oncology: anti-PD-1 non-responders.
OncoSec is investigating TAVO for treatment of metastatic melanoma and triple negative breast cancer